Medicine and Health Sciences Commons^™

A Randomized Clinical Trial Comparing Pelvic Floor Muscle Training To A Pilates Exercise Program For Improving Pelvic Muscle Strength, Patrick Culligan, Janet Scherer, Keisha Dyer, Jennifer Priestley, Geri Guingon-White, Donna Delvecchio, Margi Vangeli

Jennifer L. Priestley

Introduction and hypothesis The purpose of this study is to determine whether a Pilates exercise program and a pelvic floor muscle-training (PFMT) program could provide similar improvements in pelvic muscle strength. Methods Sixty-two women with little or no pelvic floor dysfunction were randomized to Pilates or PFMT. Each group had 24 biweekly 1-h sessions with either a physical therapist or Pilates instructor. Strength was measured via perineometry (cmH2O). Two questionnaires-pelvic floor distress inventory (PFDI-20) and pelvic floor impact questionnaire (PFIQ-7)-were also collected. Results At baseline, the Pilates and PFMT groups measured 14.9±12.5 and 12.5±10.4 cmH2O, respectively (p=0.41). Both the Pilates …

Evaluation Of A Transvaginal Mesh Delivery System For The Correction Of Pelvic Organ Prolapse: Subjective And Objective Findings At Least 1 Year After Surgery, Patrick Culligan, Paul Littman, Charbel Salamon, Jennifer Priestley, Amir Shariati

Jennifer L. Priestley

Objective: We sought to track objective and subjective outcomes ≥1 year after transvaginal mesh system to correct prolapse. Study Design: This was a retrospective cohort study of 120 women who received a transvaginal mesh procedure (Avaulta Solo, CR Bard Inc, Covington, GA). Outcomes were pelvic organ prolapse quantification values; Pelvic Floor Distress Inventory, Short Form 20/Pelvic Floor Impact Questionnaire, Short Form 7 scores; and a surgical satisfaction survey. “Surgical failure” was defined as pelvic organ prolapse quantification point >0, and/or any reports of vaginal bulge. Results: Of 120 patients, 116 (97%) were followed up for a mean of 14.4 months …

A Select Issue In The Postpartum Period: Contraception, Whitney Cowman, Abbey Hardy-Fairbanks, Jill Endres, Colleen Stockdale

Abbey J Hardy-Fairbanks

One half of pregnancies in the United States are unintended and associated with adverse pregnancy outcomes. The postpartum period is an important, yet underutilized, time to initiate contraception. The U.S. Medical Eligibility Criteria for Contraceptive Use, 2010 provides evidence-based guidelines for choosing a contraceptive method and an update in 2011 specifically addresses contraceptive method use in the puerperium. The variety of contraceptive methods include hormonal contraception, lactational amenorrhea, barrier contraception, natural family planning, and sterilization. Ideally, counseling about contraceptive choice should begin early in pregnancy care and continue postpartum; it should also include a variety of teaching modalities. Specifically we …

Risk Of Early And Late Obstetric Complications In Women With Ivf-Conceived Pregnancies And Polycystic Ovary Syndrome (Pcos), N. Bagegni, J. Blaine, Bradley Van Voorhis, A. Dokras

Bradley J Van Voorhis

No abstract provided.

Long-Term Outcomes Among Women With Cervical Cancer Treated From 1960-1987, Christopher Yopp, Jo Benda, Colleen Stockdale, Jami Shepard, Amina Ahmed

Colleen Kennedy Stockdale

To determine long term survival among women treated for cervical cancer and to provide long-term information regarding mortality and morbidity following treatment. Among a cohort of young women treated for cervical cancer over a 27 year period, with survival available up to 48 years from initial diagnosis, there were no variables identified which impacted the duration of survival beyond the initial stage of cervical cancer at presentation.

Knockdown Of Mtdh Increases Drug Sensitivity To Hdac Inhibitor And Trail Combination Treatment In Endometrial Cancer Cells, Xiangbing Meng, Pavla Brachova, Shujie Yang, Zhi Xiong, Yuping Zhang, Kimberly Leslie

Xiangbing Meng

Understanding the molecular mechanisms of chemoresistance is vital to design therapies to restore chemosensitivity. MTDH mediates drug resistance by regulating expression of genes required for the control of apoptosis and cell cycle. These findings indicate that sensitivity to chemotherapy agents and combination treatment with HDAC inhibitor and TRAIL can be restored by manipulating MTDH, and hence depletion of MTDH is a potentially novel avenue for effective cancer therapy.

The Combination Of Paclitaxel And Gefitinib Inhibits Endometrial Cancer Cells By Inducing Mitotic Catastrophe: Proof Of Principle For Dual Therapy In Endometrial Cancer, Xiangbing Meng, Laura Laidler, Lina Albitar, Anna Holmes, Donghai Dai, Thomas Buekers, David Bender, Kimberly Leslie

Xiangbing Meng

Serous uterine endometrial cancer is a lethal disease for which new therapeutic regimens are urgently needed. Combinations of chemotherapeutic agents and small molecule growth factor inhibitors have demonstrated activity in cancers from other sites. Our objective was to determine whether such a combination using Paclitaxel and Gefitinib could be active in serous endometrial cancer cells.

Phase Ii Clinical Trial Of Ixabepilone In Patients With Recurrent Or Persistent Platinum- And Taxane-Resistant Ovarian Or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study, Koen De Geest, John Blessing, Robert Morris, S. Diane Yamada, Bradley Monk, Susan Zweizig, Daniela Matei, Carolyn Muller, William Richards

Koen De Geest

PURPOSE Ixabepilone (BMS-247550) is a microtubule-stabilizing epothilone B analog with activity in taxane-resistant metastatic breast cancer. The Gynecologic Oncology Group conducted a phase II evaluation of the efficacy and safety of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant primary ovarian or peritoneal carcinoma. PATIENTS AND METHODS Patients with measurable platinum- and taxane-resistant ovarian or peritoneal carcinoma, defined as progression during or within 6 months of one prior course of treatment with each agent, received intravenous ixabepilone 20 mg/m(2) administered over 1 hour on days 1, 8, and 15 of a 28-day cycle. RESULTS Of 51 patients entered, …

A Phase Ii Study Of Docetaxel In Paclitaxel-Resistant Ovarian And Peritoneal Carcinoma: A Gynecologic Oncology Group Study, Peter Rose, John Blessing, Harrison Ball, James Hoffman, David Warshal, Koen Degeest, David Moore

Koen De Geest

OBJECTIVES: Docetaxel is an inhibitor of microtubule depolymerization and has demonstrated activity in paclitaxel-resistant breast cancer and gynecologic cancer. The Gynecologic Oncology Group (GOG) conducted a study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma to determine its activity, and nature and degree of toxicity, in this cohort of patients.

METHODS: Patients with platinum- and paclitaxel-resistant ovarian or peritoneal carcinoma, defined as progression while on or within 6 months of therapy, were eligible if they had measurable disease and had not received more than one chemotherapy regimen. Docetaxel at a dose of 100 mg/m(2) was administered iv over 1 h …

Lymphoid Enhancing Factor 1 (Lef-1) Overexpression In Epithelial Ovarian, Fallopian Tube And Peritoneal Cancer And Associations With Clinical Factors, Aine Clements, David Engle, Dawne Shelton, Traci Neff, Soo Park, David Bender, Amina Ahmed, Koen De Geest, Anna Button, John Engelhardt, Michael Goodheart

David P Bender

Lef-1 mRNA levels were statistically elevated in cases of ovarian, fallopian tube or peritoneal cancer when compared to non-cancerous controls. Among cancer cases, levels of Lef-1 were statistically different between stage and histology. Lef-1 overexpression may be predictive of poor overall survival. These findings suggest that Lef-1 overexpression may contribute to ovarian, fallopian tube and peritoneal carcinogenesis, and that further investigation is warranted.

The Combination Of Paclitaxel And Gefitinib Inhibits Endometrial Cancer Cells By Inducing Mitotic Catastrophe: Proof Of Principle For Dual Therapy In Endometrial Cancer, Xiangbing Meng, Laura Laidler, Lina Albitar, Anna Holmes, Donghai Dai, Thomas Buekers, David Bender, Kimberly Leslie

David P Bender

Serous uterine endometrial cancer is a lethal disease for which new therapeutic regimens are urgently needed. Combinations of chemotherapeutic agents and small molecule growth factor inhibitors have demonstrated activity in cancers from other sites. Our objective was to determine whether such a combination using Paclitaxel and Gefitinib could be active in serous endometrial cancer cells.

Women’S Health Educational Opportunities At The University Of Iowa’S Department Of Obstetrics And Gynecology, Marygrace Elson

Marygrace Elson

The Department of Obstetrics and Gynecology’s educational programs span a continuum of learners from undergraduate premedical students to continuing education for practicing providers in Iowa and nearby states. The Department of Obstetrics and Gynecology is committed to teaching women-centered, compassionate, evidence-based care and fostering life-long learning. The Department of Obstetrics and Gynecology is a part of the Roy J. and Lucille A. Carver College of Medicine and the University of Iowa Health Care at the University of Iowa.

Formative Feedback On A Patient-Based Assessment: Comparing Student Perceptions Of Two Feedback Methods, Marygrace Elson, Rick Axelson

Marygrace Elson

Introduction: Although formative feedback is widely recognized as an essential aid to student learning, there is little evidence regarding effective ways of providing formative feedback on structured clinical exams. This study compares students’ perceptions of immediate, face-to-face feedback with delayed, written on-line faculty feedback on their Obstetrics and Gynecology medical student clerkship patient-based assessment (PBA) at the University of Iowa.

Methods: 163 third year medical students performed the PBA between October 2009-10. Students were assigned to immediate face-to-face or delayed, written on-line feedback. Students were then invited to participate in an anonymous web-based survey. Independent samples t-tests were used to …

The Influence Of Fetal Sex On Patterns Of Change In Anti-Mullerian Hormone During Pregnancy, Ryan Empey, Donna Santillan, Mark Santillan, Eric Tyler, Stephen Hunter, Elaine Smith, Barbara Stegmann

Mark K. Santillan

Maternal anti-mullerian hormone declines sharply between 13-15 weeks, likely as a result of feto-placental signaling. Fetal AMH levels are known to be widely disparate after the first trimester, with high levels in male and absent levels in female. However, it is unclear as to whether differing fetal AMH levels influence the pattern of change of maternal AMH. Our objective was to examine AMH throughout gestation to determine if the maternal concentration varies according to the gender of the fetus.